Angela Dispenzieri

Mayo Clinic — United States

Medicine · Health Sciences

144h-index97.9kcitations2.5kworks2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(953), Amyloidosis: Diagnosis, Treatment, Outcomes(823), Protein Degradation and Inhibitors(252), Chronic Lymphocytic Leukemia Research(225), Parathyroid Disorders and Treatments(220)

Publications2.0k total

POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia
Blood Advances·2026Open Access
Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study
Blood Advances·2025Open Access
Diagnostic Performance and Interpreter Experience of 1-Hour Versus 3-Hour <sup>99m</sup> Tc-HMDP Cardiac Amyloid Radionuclide Imaging: A Prospective, Blinded Comparison
Circulation Cardiovascular Imaging·2025· 1 cited
New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System
Journal of Clinical Oncology·2025Open Access
POEMS syndrome: diagnosis, treatments, and outcomes
Hematology·2025Open Access
Comparative performance of 99mTc-pyrophosphate vs. 99mTc-hydroxymethylene diphosphonate for cardiac amyloid radionuclide imaging
Journal of Nuclear Cardiology·2025
A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary
Future Cardiology·2025Open Access
Isatuximab: surface strike, deep response in AL amyloidosis
Blood·2025Open Access
Anti-platelet factor 4 antibodies in MGUS-related thrombosis
Blood·2025Open Access
Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies
Blood·2025Open Access
A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era
Blood·2025
Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)
Blood·2025
The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma
Blood·2025Open Access
Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis
Blood·2025Open Access
MAPK pathway-driven metabolic-inflammatory axis in AL amyloidosis
Blood·2025
Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)
Blood·2025
Single-cell transcriptomics reveals proliferative, immune-evasive, and bone marrow–independent transcriptional programs in extramedullary multiple myeloma.
Blood·2025Open Access
Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement
Blood·2025Open Access
Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma - a single center prospective study
Blood·2025Open Access
Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia
Blood·2025Open Access
page 1 of 101Next →

Frequent Co-authors

Robert A. Kyle(31), S. Vincent Rajkumar(30), Morie A. Gertz(26), Shaji Kumar(20), Rafaël Fonseca(19), Martha Q. Lacy(17), John A. Lust(15), Philip R. Greipp(14), Terry M. Therneau(11), Giampaolo Merlini(10), Dirk R. Larson(10), Suzanne R. Hayman(10), Steven R. Zeldenrust(10), Thomas E. Witzig(9), Francis K. Buadi(8), Stephen J. Russell(8), David Dingli(7), Martha Grogan(7), Nelson Leung(7), Brian G.M. Durie(6)